George Sgouros

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. ncbi MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy
    George Sgouros
    Department of Radiology and Radiological Science, School of Medicine, Johns Hopkins University, Baltimore, Maryland 21231, USA
    J Nucl Med 51:311-28. 2010
  2. ncbi Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software
    George Sgouros
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Nucl Med 45:1366-72. 2004
  3. ncbi Introduction to kidney dose-response for radionuclide therapy
    George Sgouros
    Division of Nuclear Medicine, Johns Hopkins University School of Medicine, 220 Ross, 720 Rutland Avenue, Baltimore, MD 21205, USA
    Cancer Biother Radiopharm 19:357-8. 2004
  4. ncbi MIRD commentary: proposed name for a dosimetry unit applicable to deterministic biological effects--the barendsen (Bd)
    George Sgouros
    Department of Radiology and Radiological Science, School of Medicine, Johns Hopkins University, Baltimore, Maryland 21231, USA
    J Nucl Med 50:485-7. 2009
  5. ncbi Dosimetry of internal emitters
    George Sgouros
    Department of Radiology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    J Nucl Med 46:18S-27S. 2005
  6. ncbi Update: molecular radiotherapy: survey and current status
    George Sgouros
    The Russell H Morgan Department of Radiology and Radiological Science, Johns Hopkins University, School of Medicine, Baltimore, MD 21231, USA
    Cancer Biother Radiopharm 23:531-40. 2008
  7. ncbi Cancer stem cell targeting using the alpha-particle emitter, 213Bi: mathematical modeling and feasibility analysis
    George Sgouros
    Division of Nuclear Medicine, Russell H Morgan Department of Radiology and Radiological Science, Johns Hopkins University, School of Medicine, Baltimore, MD 21231, USA
    Cancer Biother Radiopharm 23:74-81. 2008
  8. ncbi MIRD continuing education: Bystander and low dose-rate effects: are these relevant to radionuclide therapy?
    George Sgouros
    School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA
    J Nucl Med 48:1683-91. 2007
  9. ncbi Lung toxicity in radioiodine therapy of thyroid carcinoma: development of a dose-rate method and dosimetric implications of the 80-mCi rule
    George Sgouros
    Division of Nuclear Medicine, Russell H Morgan Department of Radiology and Radiological Science, School of Medicine, Johns Hopkins University, Baltimore, MD 21231, USA
    J Nucl Med 47:1977-84. 2006
  10. ncbi Three-dimensional radiobiological dosimetry (3D-RD) with 124I PET for 131I therapy of thyroid cancer
    George Sgouros
    The Russell H Morgan Department of Radiology, Division of Nuclear Medicine, Johns Hopkins University, School of Medicine, Baltimore, MD, USA
    Eur J Nucl Med Mol Imaging 38:S41-7. 2011

Research Grants

  1. Dose-Response in Radionuclide Therapy
    George Sgouros; Fiscal Year: 2009
  2. Targeted Alpha-Particle Emitter Therapy of Metastases
    George Sgouros; Fiscal Year: 2009
  3. Dose-Response in Radionuclide Therapy
    George Sgouros; Fiscal Year: 2007
  4. Targeted Alpha-Particle Emitter Therapy of Metastases
    George Sgouros; Fiscal Year: 2007
  5. MODELING AND DOSIMETRY FOR RADIOLABELED ANTIBODY THERAPY
    George Sgouros; Fiscal Year: 2002
  6. Dose-Response in Radionuclide Therapy
    George Sgouros; Fiscal Year: 2010

Detail Information

Publications74

  1. ncbi MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy
    George Sgouros
    Department of Radiology and Radiological Science, School of Medicine, Johns Hopkins University, Baltimore, Maryland 21231, USA
    J Nucl Med 51:311-28. 2010
    ..The objective of this work is to review those aspects of the field that are pertinent to targeted alpha-particle emitter therapy and to provide guidance and recommendations for human alpha-particle emitter dosimetry...
  2. ncbi Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software
    George Sgouros
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Nucl Med 45:1366-72. 2004
    ..This input has typically been obtained from SPECT and planar imaging studies. The objective was to implement and evaluate PET-based, patient-specific, 3D dosimetry for thyroid cancer patients...
  3. ncbi Introduction to kidney dose-response for radionuclide therapy
    George Sgouros
    Division of Nuclear Medicine, Johns Hopkins University School of Medicine, 220 Ross, 720 Rutland Avenue, Baltimore, MD 21205, USA
    Cancer Biother Radiopharm 19:357-8. 2004
  4. ncbi MIRD commentary: proposed name for a dosimetry unit applicable to deterministic biological effects--the barendsen (Bd)
    George Sgouros
    Department of Radiology and Radiological Science, School of Medicine, Johns Hopkins University, Baltimore, Maryland 21231, USA
    J Nucl Med 50:485-7. 2009
    ..This commentary reviews recent proposals related to this issue and concludes with a recommendation to establish a new named quantity...
  5. ncbi Dosimetry of internal emitters
    George Sgouros
    Department of Radiology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    J Nucl Med 46:18S-27S. 2005
    ..Until such methods are developed and validated, absorbed dose remains an important variable--but still one of several--likely to predict response in an individual patient...
  6. ncbi Update: molecular radiotherapy: survey and current status
    George Sgouros
    The Russell H Morgan Department of Radiology and Radiological Science, Johns Hopkins University, School of Medicine, Baltimore, MD 21231, USA
    Cancer Biother Radiopharm 23:531-40. 2008
    ..In contrast to chemotherapy, wherein all proliferating cells are affected, MRT delivers radiation to only those cells that express cancer markers...
  7. ncbi Cancer stem cell targeting using the alpha-particle emitter, 213Bi: mathematical modeling and feasibility analysis
    George Sgouros
    Division of Nuclear Medicine, Russell H Morgan Department of Radiology and Radiological Science, Johns Hopkins University, School of Medicine, Baltimore, MD 21231, USA
    Cancer Biother Radiopharm 23:74-81. 2008
    ....
  8. ncbi MIRD continuing education: Bystander and low dose-rate effects: are these relevant to radionuclide therapy?
    George Sgouros
    School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA
    J Nucl Med 48:1683-91. 2007
    ....
  9. ncbi Lung toxicity in radioiodine therapy of thyroid carcinoma: development of a dose-rate method and dosimetric implications of the 80-mCi rule
    George Sgouros
    Division of Nuclear Medicine, Russell H Morgan Department of Radiology and Radiological Science, School of Medicine, Johns Hopkins University, Baltimore, MD 21231, USA
    J Nucl Med 47:1977-84. 2006
    ..This is particularly important, for example, in pediatric patients exhibiting diffuse lung metastases. The approach also highlights the impact of altered radioiodine kinetics as seen with recombinant human thyroid-stimulating hormone...
  10. ncbi Three-dimensional radiobiological dosimetry (3D-RD) with 124I PET for 131I therapy of thyroid cancer
    George Sgouros
    The Russell H Morgan Department of Radiology, Division of Nuclear Medicine, Johns Hopkins University, School of Medicine, Baltimore, MD, USA
    Eur J Nucl Med Mol Imaging 38:S41-7. 2011
    ..We highlight specific examples of such calculations and discuss the potential impact of (124)I PET/CT on thyroid cancer therapy...
  11. ncbi Toward patient-friendly cell-level dosimetry
    George Sgouros
    Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
    J Nucl Med 48:496-7. 2007
  12. ncbi Modelling and dosimetry for alpha-particle therapy
    George Sgouros
    Russel H Morgan Department of Radiology and Radiological Science, Johns Hopkins University, School of Medicine, Baltimore, MD 21231, USA
    Curr Radiopharm 4:261-5. 2011
    ..These considerations along with a discussion of the appropriate physical quantity and related units for alpha-particle radiopharmaceutical therapy are examined in this review...
  13. ncbi A treatment planning method for sequentially combining radiopharmaceutical therapy and external radiation therapy
    Robert F Hobbs
    Johns Hopkins University, Baltimore, MD 21231, USA
    Int J Radiat Oncol Biol Phys 80:1256-62. 2011
    ..We have developed and tested a treatment planning method, using the patient-specific three-dimensional dosimetry package 3D-RD, for sequentially combined RPT/XRT therapy designed to limit toxicity to organs at risk...
  14. ncbi Radioimmunotherapy of breast cancer metastases with alpha-particle emitter 225Ac: comparing efficacy with 213Bi and 90Y
    Hong Song
    Division of Nuclear Medicine, Russell H Morgan Department of Radiology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
    Cancer Res 69:8941-8. 2009
    ..These data suggest (225)Ac-labeled anti-HER-2/neu monoclonal antibody could significantly prolong survival in HER-2/neu-positive metastatic breast cancer patients...
  15. ncbi Arterial wall dosimetry for non-Hodgkin lymphoma patients treated with radioimmunotherapy
    Robert F Hobbs
    Johns Hopkins University, Baltimore Maryland 21231, USA
    J Nucl Med 51:368-75. 2010
    ..Therefore, we present a model of aortic wall toxicity based on data from 4 patients treated with (131)I-tositumomab...
  16. ncbi 213Bi (alpha-emitter)-antibody targeting of breast cancer metastases in the neu-N transgenic mouse model
    Hong Song
    Divisions of Nuclear Medicine and Neuroradiology, Russell H Morgan Department of Radiology and Radiological Science, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA
    Cancer Res 68:3873-80. 2008
    ..Analysis of the results suggests that further gains in efficacy may require higher specific activity constructs or target antigens that are more highly expressed on tumor cells...
  17. ncbi Alpha-particle emitting atomic generator (Actinium-225)-labeled trastuzumab (herceptin) targeting of breast cancer spheroids: efficacy versus HER2/neu expression
    Ase M Ballangrud
    Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Clin Cancer Res 10:4489-97. 2004
    ..225)Ac has a 10-day half-life and a decay scheme yielding four alpha-particles...
  18. ncbi Three-dimensional radiobiologic dosimetry: application of radiobiologic modeling to patient-specific 3-dimensional imaging-based internal dosimetry
    Andrew R Prideaux
    Russell H Morgan Department of Radiology and Radiological Sciences, School of Medicine, Johns Hopkins University, Baltimore, Maryland 21231, USA
    J Nucl Med 48:1008-16. 2007
    ..The methodology is illustrated using data from a thyroid cancer patient treated with radioiodine...
  19. ncbi Therapeutic potential of 90Y- and 131I-labeled anti-CD20 monoclonal antibody in treating non-Hodgkin's lymphoma with pulmonary involvement: a Monte Carlo-based dosimetric analysis
    Hong Song
    Division of Nuclear Medicine, Russell H Morgan Department of Radiology and Radiological Science, School of Medicine, Johns Hopkins University, Baltimore, Maryland 21231, USA
    J Nucl Med 48:150-7. 2007
    ..In this work, we used Monte Carlo-based dosimetry to compare the potential of (90)Y and (131)I, based purely on their emission properties, in targeted therapy for NHL lung metastases of various nodule sizes and tumor burdens...
  20. ncbi Lung dosimetry for radioiodine treatment planning in the case of diffuse lung metastases
    Hong Song
    Division of Nuclear Medicine, Russell H Morgan Department of Radiology and Radiological Science, School of Medicine, Johns Hopkins University, Baltimore, MD 21231, USA
    J Nucl Med 47:1985-94. 2006
    ..CONCLUSION: MCNP4b-based, patient-specific 3D dosimetry is feasible and important in the dosimetry of thyroid cancer patients with avid lung metastases that exhibit prolonged retention in the lungs...
  21. ncbi Patient-specific, 3-dimensional dosimetry in non-Hodgkin's lymphoma patients treated with 131I-anti-B1 antibody: assessment of tumor dose-response
    George Sgouros
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Nucl Med 44:260-8. 2003
    ....
  22. ncbi Tumor dosimetry and response for 153Sm-ethylenediamine tetramethylene phosphonic acid therapy of high-risk osteosarcoma
    Srinivasan Senthamizhchelvan
    Division of Nuclear Medicine, Russell H Morgan Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore, MD, USA
    J Nucl Med 53:215-24. 2012
    ..We also studied the biologic implication of the nonuniform tumor AD distribution using radiobiologic modeling and examined the relationship between tumor AD and response...
  23. ncbi A model of cellular dosimetry for macroscopic tumors in radiopharmaceutical therapy
    Robert F Hobbs
    Johns Hopkins University, Baltimore, Maryland 21231, USA
    Med Phys 38:2892-903. 2011
    ..The authors present here an adaptation of the simple sphere-based model from which cellular level dosimetry for macroscopic tumors and their end point quantities, such as TCP, may be extrapolated more reliably...
  24. ncbi Estimates of radiation-absorbed dose to kidneys in patients treated with 90Y-ibritumomab tiuxetan
    Sébastien Baechler
    The Russell H Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University, School of Medicine, Baltimore, MD, USA
    Cancer Biother Radiopharm 23:633-9. 2008
    ....
  25. ncbi Tandem dosing of samarium-153 ethylenediamine tetramethylene phosphoric acid with stem cell support for patients with high-risk osteosarcoma
    David M Loeb
    Division of Pediatric Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland 21231, USA
    Cancer 116:5470-8. 2010
    ..The authors conducted a phase 2 study to test safety and response of high-risk osteosarcoma to tandem doses of 153Sm-EDTMP and to determine correlation between radiation delivered by low and high administered activities...
  26. ncbi Mitigation of radiation nephropathy after internal alpha-particle irradiation of kidneys
    Jaspreet Singh Jaggi
    Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Int J Radiat Oncol Biol Phys 64:1503-12. 2006
    ..We attempted to modify pharmacologically, the functional and morphologic changes in mouse kidneys after injection with the actinium ((225)Ac) nanogenerator, an in vivo generator of alpha- and beta-particle emitting elements...
  27. ncbi Immunoliposomal delivery of 213Bi for alpha-emitter targeting of metastatic breast cancer
    Mohanambe Lingappa
    Russell H Morgan Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore, MD, USA
    Cancer Res 70:6815-23. 2010
    ..5). We have shown that the (213)Bi radiolabeled immunoliposomes are effective in treating early-stage micrometastases, giving median survival times similar to those obtained with antibody-mediated delivery of (213)Bi in this animal model...
  28. ncbi Radiation dosimetry of 82Rb in humans under pharmacologic stress
    Srinivasan Senthamizhchelvan
    Russell H Morgan Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore, MD, USA
    J Nucl Med 52:485-91. 2011
    ..Using human biokinetic measurements, in vivo, we recently reported on the resting-state dosimetry of this agent. The objective of this study was to obtain (82)Rb dose estimates under stress...
  29. ncbi Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer
    Steve Y Cho
    Russell H Morgan Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore, Maryland 21287 0014, USA
    J Nucl Med 53:1883-91. 2012
    ..Here, we describe the initial clinical experience and radiation dosimetry of (18)F-DCFBC in men with metastatic PCa...
  30. ncbi A gamma camera count rate saturation correction method for whole-body planar imaging
    Robert F Hobbs
    Johns Hopkins University, Baltimore MD, USA
    Phys Med Biol 55:817-31. 2010
    ..e. time-dependent dead-time effects. The algorithm presented here accomplishes this task...
  31. ncbi 124I PET-based 3D-RD dosimetry for a pediatric thyroid cancer patient: real-time treatment planning and methodologic comparison
    Robert F Hobbs
    Department of Radiology, Johns Hopkins University, Baltimore, Maryland 21231, USA
    J Nucl Med 50:1844-7. 2009
    ..A retrospective analysis of the conventional methodologies with appropriate corrections yielded absorbed dose estimates consistent with 3D-RD...
  32. ncbi Comparison of organ residence time estimation methods for radioimmunotherapy dosimetry and treatment planning--patient studies
    Bin He
    Russell H Morgan Department of Radiology and Radiological Science, Johns Hopkins Medical Institutions, Baltimore, Maryland 21287, USA
    Med Phys 36:1595-601. 2009
    ..More sophisticated methods, such as the hybrid SPECT/planar method investigated here, are likely to be better predictors of organ dose and, as a result, organ toxicities...
  33. ncbi Pharmacokinetics and Biodistribution of (86)Y-Trastuzumab for (90)Y dosimetry in an ovarian carcinoma model: correlative MicroPET and MRI
    Stig Palm
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Nucl Med 44:1148-55. 2003
    ..MicroPET and MRI-based preclinical biodistribution and localization data were obtained and used to assess the therapeutic potential of (90)Y-trastuzumab monoclonal antibody (mAb) (anti-HER2/neu) against ovarian carcinoma...
  34. ncbi Human biodistribution and radiation dosimetry of 82Rb
    Srinivasan Senthamizhchelvan
    Division of Nuclear Medicine, Russell H Morgan Department of Radiology, Johns Hopkins University, Baltimore, Maryland 21287, USA
    J Nucl Med 51:1592-9. 2010
    ..Prior estimates of radiation-absorbed doses from (82)Rb, a frequently used PET perfusion tracer, yielded discrepant results. We reevaluated (82)Rb dosimetry using human in vivo biokinetic measurements...
  35. ncbi Efforts to control the errant products of a targeted in vivo generator
    Jaspreet Singh Jaggi
    Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer Res 65:4888-95. 2005
    ..0001). Metal chelation, diuresis with furosemide or chlorothiazide, and competitive metal blockade may be used as adjuvant therapies to modify the renal accumulation of 225Ac daughters...
  36. ncbi 2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer
    Ying Chen
    Russell H Morgan Department of Radiology and Radiological Science, Johns Hopkins Medical School, Baltimore, Maryland, USA
    Clin Cancer Res 17:7645-53. 2011
    ..PSMA is upregulated in prostate cancer epithelia and in the neovasculature of most solid tumors...
  37. ncbi Renal tubulointerstitial changes after internal irradiation with alpha-particle-emitting actinium daughters
    Jaspreet Singh Jaggi
    Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Am Soc Nephrol 16:2677-89. 2005
    ..These findings are dissimilar to those seen after gamma or beta irradiation of kidneys...
  38. ncbi Extension of the biological effective dose to the MIRD schema and possible implications in radionuclide therapy dosimetry
    Sébastien Baechler
    Russell H Morgan Department of Radiology and Radiological Sciences, School of Medicine, Johns Hopkins University, Baltimore, Maryland 21231, USA
    Med Phys 35:1123-34. 2008
    ..The MIRD-based BED formalism is expected to be useful for patient-specific adjustments of activity and to facilitate the investigation of dose-toxicity correlations with respect to dose-rate and tissue repair mechanism...
  39. ncbi Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia
    Todd L Rosenblat
    Department of Medicine and the Molecular Pharmacology and Chemistry Program, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Cancer Res 16:5303-11. 2010
    ..This phase I/II trial was conducted to determine the maximum tolerated dose (MTD) and antileukemic effects of (213)Bi-lintuzumab, the first targeted α-emitter, after partially cytoreductive chemotherapy...
  40. ncbi Evaluation of quantitative imaging methods for organ activity and residence time estimation using a population of phantoms having realistic variations in anatomy and uptake
    Bin He
    Russell H Morgan Department of Radiology and Radiological Science, Johns Hopkins Medical Institutions, Baltimore, Maryland 21287 0859, USA
    Med Phys 36:612-9. 2009
    ..The QPlanar or hybrid QPlanar/QSPECT methods had mean errors and standard deviations of errors that approached those of pure QSPECT while providing simplified image acquisition protocols, and thus may be more clinically practical...
  41. ncbi An immunotolerant HER-2/neu transgenic mouse model of metastatic breast cancer
    Hong Song
    Division of Nuclear Medicine, School of Medicine, Johns Hopkins University, Baltimore, MD 21231, USA
    Clin Cancer Res 14:6116-24. 2008
    ..We have developed and characterized a preclinical model for the evaluation of immune-mediated metastatic breast cancer therapies...
  42. ncbi Three-dimensional imaging-based radiobiological dosimetry
    George Sgouros
    The Russell H Morgan Department of Radiology and Radiological Science, Johns Hopkins University, School of Medicine, Baltimore, MD 21231, USA
    Semin Nucl Med 38:321-34. 2008
    ..Given the attendant logistical and financial costs, a demonstrated improvement in patient care will be a prerequisite for the adoption of such highly-patient specific internal dosimetry methods...
  43. ncbi Enhanced retention of the alpha-particle-emitting daughters of Actinium-225 by liposome carriers
    Stavroula Sofou
    Molecular Pharmacology and Chemistry, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Bioconjug Chem 18:2061-7. 2007
    ....
  44. ncbi Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates
    Matthias Miederer
    Department of Molecular Pharmacology and Chemistry, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Nucl Med 45:129-37. 2004
    ..However, the 3 alpha-emitting daughter elements generated have the potential for significant toxicity as these nuclides are no longer bound to the carrier IgG...
  45. ncbi A bone marrow toxicity model for ²²³Ra alpha-emitter radiopharmaceutical therapy
    Robert F Hobbs
    Johns Hopkins University, Baltimore, MD, USA
    Phys Med Biol 57:3207-22. 2012
    ..These suggest that increasing the amount of radioactivity may not substantially increase the risk of toxicity, a result unavailable to the absorbed fraction method of dose calculation...
  46. ncbi Calculation of the biological effective dose for piecewise defined dose-rate fits
    Robert F Hobbs
    Department of Radiology, Johns Hopkins University, Baltimore, Maryland 21231, USA
    Med Phys 36:904-7. 2009
    ..The algorithmically calculated BED is compatible with an analytic calculation for a similarly valued exponentially fitted dose-rate plot and is the only resolution for piecewise defined dose-rate functions...
  47. ncbi Engineered liposomes for potential alpha-particle therapy of metastatic cancer
    Stavroula Sofou
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Nucl Med 45:253-60. 2004
    ..Liposomes with encapsulated (225)Ac were developed to retain the potentially toxic daughters at the tumor site...
  48. ncbi Bortezomib-induced enzyme-targeted radiation therapy in herpesvirus-associated tumors
    De Xue Fu
    Department of Oncology, Johns Hopkins School of Medicine, Baltimore, Maryland 21287, USA
    Nat Med 14:1118-22. 2008
    ..Bortezomib-induced enzyme-targeted radiation therapy illustrates the possibility of pharmacologically modulating tumor gene expression to result in targeted radiotherapy...
  49. ncbi A nephron-based model of the kidneys for macro-to-micro α-particle dosimetry
    Robert F Hobbs
    Department of Radiology, Johns Hopkins University, Baltimore MD, USA
    Phys Med Biol 57:4403-24. 2012
    ..The S-values established here will enable a MIRD-type application of α-particle dosimetry for α-emitters, i.e. measuring the TIA in the kidney (or renal cortex) will provide meaningful and accurate nephron-level dosimetry...
  50. ncbi MIRD pamphlet No. 23: quantitative SPECT for patient-specific 3-dimensional dosimetry in internal radionuclide therapy
    Yuni K Dewaraja
    Department of Radiology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    J Nucl Med 53:1310-25. 2012
    ....
  51. ncbi An approach for balancing diagnostic image quality with cancer risk: application to pediatric diagnostic imaging of 99mTc-dimercaptosuccinic acid
    George Sgouros
    Russell H Morgan Department of Radiology and Radiological Science, Johns Hopkins University, School of Medicine, Baltimore, Maryland 21231, USA
    J Nucl Med 52:1923-9. 2011
    ..Imaging guidelines, especially for pediatric patients, must balance the risks associated with radiation exposure with the need to obtain the high-quality images necessary to derive the benefits of an accurate clinical diagnosis...
  52. ncbi Targeted alpha particle immunotherapy for myeloid leukemia
    Joseph G Jurcic
    Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Medical College of Cornell University, New York, NY 10021, USA
    Blood 100:1233-9. 2002
    ..This study demonstrates the safety, feasibility, and antileukemic effects of (213)Bi-HuM195, and it is the first proof-of-concept for systemic targeted alpha particle immunotherapy in humans...
  53. ncbi Hematologic toxicity in radioimmunotherapy: dose-response relationships for I-131 labeled antibody therapy
    Joseph A O'Donoghue
    Memorial Sloan Kettering Cancer Center and Ludwig Institute for Cancer Research, New York, NY 10021, USA
    Cancer Biother Radiopharm 17:435-43. 2002
    ..Treatment may be prescribed on the basis of administered activity or absorbed dose. An optimal definition of maximum tolerated dose will enable the clinical benefits of RIT to be maximized...
  54. ncbi Improved tumor imaging and therapy via i.v. IgG-mediated time-sequential modulation of neonatal Fc receptor
    Jaspreet Singh Jaggi
    Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Clin Invest 117:2422-30. 2007
    ..The ability to reduce the serum persistence of conjugated IgG antibodies after their infusion can enhance their therapeutic index, resulting in improved therapeutic and diagnostic efficacy...
  55. ncbi Dose-finding study of 153Sm-EDTMP in patients with poor-prognosis osteosarcoma
    David M Loeb
    Division of Pediatric Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland 21231, USA
    Cancer 115:2514-22. 2009
    ..The purpose of the current study was to determine the maximally tolerated dose of (153)Sm-EDTMP that permits hematopoietic recovery within 6 weeks...
  56. ncbi Alpha-particles for targeted therapy
    George Sgouros
    Russell H Morgan Department of Radiology and Radiological Science, Johns Hopkins University, School of Medicine, Baltimore MD USA
    Adv Drug Deliv Rev 60:1402-6. 2008
    ..Results from the small number of clinical trials reported to date have shown efficacy without significant toxicity...
  57. ncbi Antibody association with HER-2/neu-targeted vaccine enhances CD8 T cell responses in mice through Fc-mediated activation of DCs
    Peter S Kim
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, 1650 Orleans Street, CRB1 4M86, Baltimore, Maryland 21231, USA
    J Clin Invest 118:1700-11. 2008
    ..This multimodality attack on the same tumor antigen may have the potential to overcome tolerance to self antigens and weaken the immunosuppressive networks within the tumor microenvironment...
  58. ncbi N-[N-[(S)-1,3-Dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-L-cysteine, [18F]DCFBC: a new imaging probe for prostate cancer
    Ronnie C Mease
    Russell H Morgan Department of Radiology, Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA
    Clin Cancer Res 14:3036-43. 2008
    ..Herein, we extend that work by preparing and testing a PSMA inhibitor of the same class labeled with fluorine-18...
  59. ncbi Murine S factors for liver, spleen, and kidney
    Katherine S Kolbert
    Imaging and Spectroscopic Physics Service, Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Nucl Med 44:784-91. 2003
    ..Absorbed fractions for 5 monoenergetic electrons, ranging in energy from 0.5 to 2 MeV, are also provided...
  60. ncbi Radioimmunotherapy of solid tumors: searching for the right target
    Hong Song
    Division of Nuclear Medicine, Russell H Morgan, Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA hsong6jhmi edu
    Curr Drug Deliv 8:26-44. 2011
    ..The review shows that the trend for radiolabeled antibodies under pre-clinical development is to also target antigens associated with signaling pathways that are essential for the growth and survival of the tumor...
  61. ncbi Trafficking of high avidity HER-2/neu-specific T cells into HER-2/neu-expressing tumors after depletion of effector/memory-like regulatory T cells
    Vivian L Weiss
    The Sidney Kimmel Cancer Center at Johns Hopkins, John Hopkins University School of Medicine, Baltimore, Maryland, United States of America
    PLoS ONE 7:e31962. 2012
    ....
  62. ncbi In vivo multicolor molecular MR imaging using diamagnetic chemical exchange saturation transfer liposomes
    Guanshu Liu
    F M Kirby Research Center for Functional Brain Imaging, Kennedy Krieger Institute, Baltimore, Maryland 21205, USA
    Magn Reson Med 67:1106-13. 2012
    ..Being nonmetallic and bioorganic, these diamagnetic chemical exchange saturation transfer liposomes form an attractive novel platform for multicolor imaging in vivo...
  63. ncbi Size-induced enhancement of chemical exchange saturation transfer (CEST) contrast in liposomes
    Jason M Zhao
    Russell H Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    J Am Chem Soc 130:5178-84. 2008
    ..These new theoretical and experimental tools are expected to benefit applications of liposomes to sensing the cellular environment, targeting and imaging biological processes, and optimizing drug delivery properties...
  64. ncbi Combination treatment with 17-N-allylamino-17-demethoxy geldanamycin and acute irradiation produces supra-additive growth suppression in human prostate carcinoma spheroids
    Richard Enmon
    Memorial Sloan-Kettering Cancer Center, New York, New York, USA
    Cancer Res 63:8393-9. 2003
    ..These results suggest that significant gains in treatment effectiveness may be obtained by combining these treatment modalities, warranting additional preclinical investigation...
  65. ncbi Blood-based red marrow dosimetry: where's the beef?
    Jeffry A Siegel
    J Nucl Med 46:1404-6; author reply 1405-6. 2005
  66. ncbi Absorbed fractions for alpha-particles in tissues of trabecular bone: considerations of marrow cellularity within the ICRP reference male
    Christopher J Watchman
    Department of Nuclear and Radiological Engineering, University of Florida, Gainesville, Florida 32611-8300, USA
    J Nucl Med 46:1171-85. 2005
    ..The data given in this study provide a more-firm basis for application of the MIRD schema to patient-specific dosimetry for newly developing therapies using alpha-particle emitters...
  67. ncbi Bone marrow dosimetry using blood-based models for radiolabeled antibody therapy: a multiinstitutional comparison
    Barry W Wessels
    Department of Radiation Oncology, Case Western Reserve University, Cleveland, Ohio
    J Nucl Med 45:1725-33. 2004
    ..A parameter sensitivity analysis and a summary discussion of the use of this model for potentially improving dose-response data correlation are also presented...
  68. ncbi Liposome-mediated radiotherapeutics within avascular tumor spheroids: comparative dosimetry study for various radionuclides, liposome systems, and a targeting antibody
    Dimitris Emfietzoglou
    Department of Medical Physics, University of Ioannina Medical School, Ioannina, Greece
    J Nucl Med 46:89-97. 2005
    ....
  69. ncbi Rationales, evidence, and design considerations for fractionated radioimmunotherapy
    Gerald L DeNardo
    Department of Internal Medicine, Division of Hematology and Oncology, Section of Radiodiagnosis and Therapy, University of California, Davis Medical Center, Sacramento, California 95816, USA
    Cancer 94:1332-48. 2002
    ....
  70. ncbi Blood and bone marrow dosimetry in radioiodine therapy of thyroid cancer
    George Sgouros
    J Nucl Med 46:899-900; author reply 901. 2005
  71. ncbi Correlation of red marrow radiation dosimetry with myelotoxicity: empirical factors influencing the radiation-induced myelotoxicity of radiolabeled antibodies, fragments and peptides in pre-clinical and clinical settings
    Thomas M Behr
    Department of Nuclear Medicine of the Philipps University of Marburg, Marburg Lahn, Germany
    Cancer Biother Radiopharm 17:445-64. 2002
    ..g., previous myelotoxic therapy, bone marrow involvement by metastatic malignancy) seem to a, bone marrow involvement by metastatic malignancy) seem to affect the resulting myelotoxicity...
  72. ncbi MIRD Pamphlet No 19: absorbed fractions and radionuclide S values for six age-dependent multiregion models of the kidney
    Lionel G Bouchet
    Department of Neurological Surgery, University of Florida, Gainesville, Florida 32611-8300, USA
    J Nucl Med 44:1113-47. 2003
    ..Full utilization of the new model, however, requires serial imaging of the kidneys with regions of interest assigned to the renal cortex and medulla...
  73. ncbi Antibody-targeted liposomes in cancer therapy and imaging
    Stavroula Sofou
    Polytechnic University, Othmer Jacobs Department of Chemical and Biological Engineering, 6 Metrotech Center, Brooklyn, NY 11201, USA
    Expert Opin Drug Deliv 5:189-204. 2008
    ..Their use in radionuclide and chemo- and radiosensitizer delivery is just emerging. Multifunctional liposomes containing 'layered functionalities' could potentially be the future direction in targeted liposome-based therapy...
  74. ncbi Binding and interstitial penetration of liposomes within avascular tumor spheroids
    Kostas Kostarelos
    Imperial College Genetic Therapies Centre, South Kensington Campus, Imperial College London, United Kingdom
    Int J Cancer 112:713-21. 2004
    ....

Research Grants17

  1. Dose-Response in Radionuclide Therapy
    George Sgouros; Fiscal Year: 2009
    ..abstract_text> ..
  2. Targeted Alpha-Particle Emitter Therapy of Metastases
    George Sgouros; Fiscal Year: 2009
    ..The work described in this application is intended to develop and evaluate such an approach. ..
  3. Dose-Response in Radionuclide Therapy
    George Sgouros; Fiscal Year: 2007
    ....
  4. Targeted Alpha-Particle Emitter Therapy of Metastases
    George Sgouros; Fiscal Year: 2007
    ..The work described in this application is intended to develop and evaluate such an approach. ..
  5. MODELING AND DOSIMETRY FOR RADIOLABELED ANTIBODY THERAPY
    George Sgouros; Fiscal Year: 2002
    ....
  6. Dose-Response in Radionuclide Therapy
    George Sgouros; Fiscal Year: 2010
    ..abstract_text> ..